Industry

Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting PCSK9 to reduce LDL-C BOSTON–(BUSINESS WIRE)–Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification … [Read more…]

– Ahead of generic alternatives to weight loss medication expected to hit the Canadian market in 2026, Phoenix’s poll also found two in five Canadians would be interested in trying them – TORONTO–(BUSINESS WIRE)–Today, Phoenix, Canada’s leading digital health clinic for men, released new poll data with insights from over 1,500 Canadians on sentiments around … [Read more…]

Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac Recovery MENLO PARK, Calif.–(BUSINESS WIRE)–#TFX–Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced positive results from the SPIRARE I first-in-human (FIH) study. Data was presented at … [Read more…]

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) … [Read more…]

Four presentations highlight 12-month clinical outcomes, as well as MRI-assessed joint protection and patient perspectives supporting the SetPoint System as first-of-its-kind treatment for rheumatoid arthritis (RA) VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the … [Read more…]

FRANKLIN, Tenn.–(BUSINESS WIRE)–Community Health Systems, Inc. (NYSE: CYH) announced today that certain subsidiaries of the Company have entered into a definitive agreement to sell 186-bed Regional Hospital of Scranton and 122-bed Moses Taylor Hospital in Scranton, Pennsylvania, 369-bed Wilkes-Barre General Hospital in Wilkes-Barre, Pennsylvania, and certain related businesses to affiliates of Tenor Health Foundation. Since … [Read more…]

BOSTON–(BUSINESS WIRE)–#PR—Ford Hutman Media (“FHM”) and Pinkergreen today announced Greenford, a new firm to support emerging biotech and life-science companies move from stealth to scale with integrated communications, brand strategy, and website development. The firm was founded by two female industry leaders, Rachel Ford Hutman, Co-Founder of Greenford and Principal at FHM, and Kelley Shaw-Wade, … [Read more…]

— XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC — — 25% overall response rate (ORR) observed within the target dose range — — First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort — — Management hosting webcast and conference call today at 1:30 p.m. ET … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Dermal Fillers Market by Brand (Juvederm, Sculptra, Radiesse), Product (Hyaluronic, Collagen, PLLA), Procedure (Skin Rejuvenation, Scar Removal, Face & Body Contouring), End User (Dermatology Clinic, Beauty Centers, Medical Spa) – Global Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The dermal fillers market is expected to experience significant growth, increasing from … [Read more…]

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study … [Read more…]